Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1374

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 6
Chunk 1374
---
Kim is not a party to any arrangement or understanding with any
person pursuant to which he was appointed as director, nor is he party to any transactions required to be disclosed under Item 404(a)
of Regulation S-K involving the Company.

As previously disclosed on the Company’s Current Report filed
on Form 8-K on March 25, 2025, on March 24, 2025 the Company Board appointed Dr. Constance Höfer as the Company’s Chief
Scientific Officer, effective on that date. Dr. Höfer is a seasoned leader in drug development with over 20 years of experience in
oncology and immunology and will oversee the Company’s scientific strategy and innovation pipeline.. Coupled with her extensive
industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology
and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development.

In connection with Dr. Höfer’s appointment, the Company
entered into an employment agreement (the “Agreement”) with Dr. Höfer, which provides for her compensation
and other employment terms. Under the Agreement, Dr. Höfer will receive:

●A base salary of $300,000.00
per year;

●Participation in Equity-based
Compensation Plan of the Company, as determined at the discretion of the Company’s Compensation Committee; and

●Other customary benefits available
to executive officers of the Company.

There are no arrangements or understandings between Dr. Höfer
and any other person pursuant to which she was selected as an officer. Additionally, Dr. Höfer does not have any family relationships
with any director or executive officer of the Company. Further, Dr. Höfer has no related-party transactions reportable under Item
404(a) of Regulation S-K.

The Company issued a press release regarding Dr. Höfer’s
appointment, which is attached as Exhibit 99.1 to the Company’s March 25, 2025 Form 8-K and is incorporated herein
by reference.

Committees of the Board of Directors 

Upon the consummation of the Business Combination, the Company Board
reconstituted its audit committee, compensation committee and corporate governance and nomination committee. The Board of Directors adopted
a new charter for each of these committees, which comply with the applicable requirements of current SEC and Nasdaq rules. The Company
intends to comply with